Cit­i­zen pe­ti­tions: FDA re­vis­es guid­ance to block drug­mak­ers from abus­ing the sys­tem

The FDA on Tues­day is­sued a re­vised draft guid­ance de­signed to al­low for the FDA to re­ject 505(q) pe­ti­tions if the agency de­ter­mines the pri­ma­ry pur­pose of the pe­ti­tion is to de­lay the ap­proval of an ab­bre­vi­at­ed new drug ap­pli­ca­tion (AN­DA).

“We be­lieve this will pro­vide an ad­di­tion­al de­ter­rent to pur­su­ing these tac­tics,” the FDA said.

The new ap­proach to re­view­ing pe­ti­tions would al­so help the FDA fo­cus its re­sources on ad­dress­ing pe­ti­tions that are most like­ly to present an ob­sta­cle to the avail­abil­i­ty of gener­ic drugs.

“Once an ap­pli­ca­tion is sub­mit­ted, the FDA has a goal date of mak­ing an ap­proval de­ci­sion on that ap­pli­ca­tion with­in 10 months, or, for some pri­or­i­ty ap­pli­ca­tions, with­in eight months. If a cit­i­zen pe­ti­tion is re­ceived while a prod­uct ap­pli­ca­tion is al­ready un­der re­view, and if the goal date for that re­view falls with­in the next 150 days, the draft guid­ance states that the FDA would ex­pect to re­spond to that pe­ti­tion with­in 150 days,” the FDA said.

Un­der the sec­tion, “How Does FDA De­ter­mine if a Pe­ti­tion Would De­lay Ap­proval of an AN­DA, 505(b)(2) Ap­pli­ca­tion, or 351(k) Ap­pli­ca­tion,” the FDA ex­plains is­sues that could im­pli­cate the pub­lic health in­clude, for ex­am­ple, “(1) whether a pro­posed gener­ic drug prod­uct is bioe­quiv­a­lent to the ref­er­ence list­ed drug or (2) whether an in­di­ca­tion can be safe­ly omit­ted from the la­bel­ing be­cause that in­di­ca­tion is pro­tect­ed by a patent.”

To fur­ther dis­suade com­pa­nies from im­prop­er­ly us­ing these pe­ti­tions, the FDA al­so said it in­tends to high­light in its an­nu­al re­port to Con­gress the de­ter­mi­na­tions of pe­ti­tions that are judged to have been sub­mit­ted to de­lay an ap­proval. The guid­ance al­so out­lines the FDA’s in­ten­tion to re­fer these mat­ters to the Fed­er­al Trade Com­mis­sion.

Oth­er ques­tions an­swered in the guid­ance in­clude, “How Does FDA De­ter­mine if Sec­tion 505(q) Ap­plies to a Par­tic­u­lar Pe­ti­tion?” and “What Is the Re­la­tion­ship Be­tween the Re­view of Pe­ti­tions Un­der Sec­tion 505(q) and the Re­view of AN­DAs, 505(b)(2) Ap­pli­ca­tions, and 351(k) Ap­pli­ca­tions for Which the Agency Has Not Yet Made a Fi­nal De­ci­sion on Ap­prov­abil­i­ty?” and “What Con­sid­er­a­tions May Sug­gest That a Pe­ti­tion Was Sub­mit­ted for the Pri­ma­ry Pur­pose of De­lay­ing Ap­proval of an Ap­pli­ca­tion?”

This 17-page guid­ance, up­dat­ing a pre­vi­ous ver­sion from 2014, al­so de­scribes how FDA in­ter­prets the pro­vi­sions of sec­tion 505(q) re­quir­ing that (1) a pe­ti­tion in­clude a cer­ti­fi­ca­tion and (2) sup­ple­men­tal in­for­ma­tion or com­ments to a pe­ti­tion in­clude a ver­i­fi­ca­tion.


First pub­lished here. Reg­u­la­to­ry Fo­cus is the flag­ship on­line pub­li­ca­tion of the Reg­u­la­to­ry Af­fairs Pro­fes­sion­als So­ci­ety (RAPS), the largest glob­al or­ga­ni­za­tion of and for those in­volved with the reg­u­la­tion of health­care and re­lat­ed prod­ucts, in­clud­ing med­ical de­vices, phar­ma­ceu­ti­cals, bi­o­log­ics and nu­tri­tion­al prod­ucts. Email news@raps.org for more in­for­ma­tion.

Author

Zachary Brennan

managing editor, RAPS

John Hood [file photo]

UP­DATE: Cel­gene and the sci­en­tist who cham­pi­oned fe­dra­tinib's rise from Sanofi's R&D grave­yard win FDA OK

Six years after Sanofi gave it up for dead, the FDA has approved the myelofibrosis drug fedratinib, now owned by Celgene.

The drug will be sold as Inrebic, and will soon land in the portfolio at Bristol-Myers Squibb, which is finalizing a deal to acquire Celgene.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,400+ biopharma pros reading Endpoints daily — and it's free.

UP­DAT­ED: AveX­is sci­en­tif­ic founder was axed — and No­var­tis names a new CSO in wake of an ethics scan­dal

Now at the center of a storm of controversy over its decision to keep its knowledge of manipulated data hidden from regulators during an FDA review, Novartis CEO Vas Narasimhan has found a longtime veteran in the ranks to head the scientific work underway at AveXis, where the incident occurred. And the scientific founder has hit the exit.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,400+ biopharma pros reading Endpoints daily — and it's free.

Ab­b­Vie gets its FDA OK for JAK in­hibitor upadac­i­tinib, but don’t look for this one to hit ex­ecs’ lofty ex­pec­ta­tions

Another big drug approval came through on Friday afternoon as the FDA OK’d AbbVie’s upadacitinib — an oral JAK1 inhibitor that is hitting the rheumatoid arthritis market with a black box warning of serious malignancies, infections and thrombosis reflecting fears associated with the class.

It will be sold as Rinvoq — at a wholesale price of $59,000 a year — and will likely soon face competition from a drug that AbbVie once controlled, and spurned. Reuters reports that a 4-week supply of Humira, by comparison, is $5,174, adding up to about $67,000 a year.

The top 10 fran­chise drugs in bio­phar­ma his­to­ry will earn a to­tal of $1.4T (tril­lion) by 2024 — what does that tell us?

Just in case you were looking for more evidence of just how important Amgen’s patent win on Enbrel is for the company and its investors, EvaluatePharma has come up with a forward-looking consensus estimate on what the list of top 10 drugs will look like in 2024.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,400+ biopharma pros reading Endpoints daily — and it's free.

UP­DAT­ED: Sci­en­tist-CEO ac­cused of im­prop­er­ly us­ing con­fi­den­tial in­fo from uni­corn Alec­tor

The executive team at Alector $ALEC has a bone to pick with scientific co-founder Asa Abeliovich. Their latest quarterly rundown has this brief note buried inside:

On June 18, 2019, we initiated a confidential arbitration proceeding against Dr. Asa Abeliovich, our former consulting co-founder, related to alleged breaches of his consulting agreement and the improper use of our confidential information that he learned during the course of rendering services to us as our consulting Chief Scientific Officer/Chief Innovation Officer. We are in the early stage of this arbitration proceeding and are unable to assess or provide any assurances regarding its possible outcome.

There’s no explicit word in the filing on what kind of confidential info was involved, but the proceeding got started 2 days ahead of Abeliovich’s IPO.

Abeliovich, formerly a tenured associate professor at Columbia, is a top scientist in the field of neurodegeneration, which is where Alector is targeted. More recently, he’s also helped start up Prevail Therapeutics as the CEO, which raised $125 million in an IPO. And there he’s planning on working on new gene therapies that target genetically defined subpopulations of Parkinson’s disease. Followup programs target Gaucher disease, frontotemporal dementia and synucleinopathies.

But this time Abeliovich is the CEO rather than a founding scientist. And some of their pipeline overlaps with Alector’s.

Abeliovich and Prevail, though, aren’t taking this one lying down.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,400+ biopharma pros reading Endpoints daily — and it's free.

Chi­na has be­come a CEO-lev­el pri­or­i­ty for multi­na­tion­al phar­ma­ceu­ti­cal com­pa­nies: the trend and the im­pli­ca­tions

After a “hot” period of rapid growth between 2009 and 2012, and a relatively “cooler” period of slower growth from 2013 to 2015, China has once again become a top-of-mind priority for the CEOs of most large, multinational pharmaceutical companies.

At the International Pharma Forum, hosted in March in Beijing by the R&D Based Pharmaceutical Association Committee (RDPAC) and the Pharmaceutical Research and Manufacturers of America (PhRMA), no fewer than seven CEOs of major multinational pharmaceutical firms participated, including GSK, Eli Lilly, LEO Pharma, Merck KGaA, Pfizer, Sanofi and UCB. A few days earlier, the CEOs of several other large multinationals attended the China Development Forum, an annual business forum hosted by the research arm of China’s State Council. It’s hard to imagine any other country, except the US, having such drawing power at CEO level.

As dis­as­ter struck, Ab­b­Vie’s Rick Gon­za­lez swooped in on Al­ler­gan with an of­fer Brent Saun­ders couldn’t say no to

Early March was a no good, awful, terrible time for Allergan CEO Brent Saunders. His big lead drug had imploded in a Phase III disaster and activists were after his hide — or at least his chairman’s title — as the stock price continued a steady droop that had eviscerated share value for investors.

But it was a perfect time for AbbVie CEO Rick Gonzalez to pick up the phone and ask Saunders if he’d like to consider a “strategic” deal.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,400+ biopharma pros reading Endpoints daily — and it's free.

CEO Pascal Soriot via Getty Images

As­traZeneca's jug­ger­naut PARP play­er Lyn­parza scoops up an­oth­er dom­i­nant win in PhI­II as the FDA adds a 'break­through' for Calquence

AstraZeneca’s oncology R&D group under José Baselga keeps churning out hits.

Wednesday morning the pharma giant and their partners at Merck parted the curtains on a successful readout for their Phase III PAOLA-1 study, demonstrating statistically significant improvement in progression-free survival for women with ovarian cancer in a first-line maintenance setting who added their PARP Lynparza to Avastin. This is their second late-stage success in ovarian cancer, which will help stave off rivals like GSK.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,400+ biopharma pros reading Endpoints daily — and it's free.

ICER blasts FDA, PTC and Sarep­ta for high prices on DMD drugs Em­flaza, Ex­ondys 51

ICER has some strong words for PTC, Sarepta and the FDA as the US drug price watchdog concludes that as currently priced, their respective new treatments for Duchenne muscular dystrophy are decidedly not cost-effective.

The final report — which cements the conclusions of a draft issued in May — incorporates the opinion of a panel of 17 experts ICER convened in a public meeting last month. It also based its analysis of Emflaza (deflazacort) and Exondys 51 (eteplirsen) on updated annual costs of $81,400 and over $1 million, respectively, after citing “incorrect” lower numbers in the initial calculations.